



Breaking Barriers in Mental Health: Novel Targets and Therapies for Depression and Anxiety

Muhammad Irfan Bashir¹

¹Faculty of Pharmacy, Universiti Sultan Zainal Abidin, Besut Campus, Terengganu, Malaysia
irfanbashir@unisza.edu.my

ARTICLE INFO

How to Cite:

Bashir, M. I. (2024). Breaking Barriers in Mental Health: Novel Targets and Therapies for Depression and Anxiety. *Pakistan BioMedical Journal*, 7(12). <https://doi.org/10.54393/pbmj.v7i12.1204>

Depression and anxiety are among the most prevalent mental health disorders, posing significant challenges to individuals and society. Despite the widespread use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), many patients fail to achieve full remission or encounter debilitating side effects. This underscores an urgent need for innovative therapeutic approaches that go beyond traditional monoaminergic systems, targeting new pathways and mechanisms involved in these complex disorders.

Recent advances have highlighted promising therapeutic targets, including the glutamatergic system. Ketamine, an NMDA receptor antagonist, has demonstrated rapid and sustained improvements in mood, inspiring the development of drugs that modulate glutamate transmission. Other systems, such as neuropeptides like oxytocin and vasopressin, are gaining attention for their roles in emotional regulation, while the endocannabinoid system offers potential for regulating mood and stress response [1].

Another recent study have shown that ketamine may offer significant benefits for individuals with psychiatric conditions such as treatment-resistant bipolar depression. Evidence suggests that even a single dose of intranasal ketamine can produce swift antidepressant effects, offering an alternative option for patients unresponsive to standard treatments [2]. These novel approaches bring significant challenges with them. The safety profile of new agents must be rigorously evaluated to avoid unintended consequences, and regulatory barriers can delay the availability of innovative therapies. Moreover, the heterogeneity of depression and anxiety, influenced by genetic, environmental, and social factors, highlights the need for personalised medicine. Future research must prioritise understanding these differences to optimise treatment outcomes for diverse populations.

The exploration of novel targets and drugs signals a paradigm shift in the treatment of depression and anxiety, moving away from a one-size-fits-all approach toward tailored interventions. These advancements bring renewed hope to millions of patients worldwide, promising more effective, rapid, and sustainable relief. With ongoing research and careful clinical translation, these innovative therapies have the potential to transform mental health care in the coming decades.

REFERENCES

- [1] 1. Njenga, C., Ramanuj, P. P., de Magalhães, F. J. C., & Pincus, H. A. (2024). New and emerging treatments for major depressive disorder. *The BMJ*, 386, e073823. <https://doi.org/10.1136/bmj-2022-073823>
- [2] Jones, G. H., Vecera, C. M., Ruiz, A. C., Wu, H. E., McInturff, S. I., Orejarena, M. J., Smith, K. A., Soares, J. C., Zarate, C. A., Lane, S. D., & Machado-Vieira, R. (2024). A randomized, double-blind, placebo-controlled pilot trial of the acute antisuicidal and antidepressant effects of intranasal (R,S)-ketamine in severe unipolar and bipolar depression with and without comorbid alcohol use disorder. *Journal of Clinical Psychiatry*, 85(2), 23m14974. <https://doi.org/10.4088/JCP.23m14974>